Antipsychotic Medications

New Research from the CWMH: Evaluating the Risk of Major Malformations in Children Prenatally Exposed to Atypical Antipsychotics

Despite the increasing use of the newer “atypical” or second-generation antipsychotic agents to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders, we have relatively little data [...]

By |2016-07-12T15:30:24-04:00July 11th, 2016|Antipsychotic Medications, Outcomes, Pregnancy & Medications, Research at CWMH, Risk of Malformations|Comments Off on New Research from the CWMH: Evaluating the Risk of Major Malformations in Children Prenatally Exposed to Atypical Antipsychotics

New Research from the CWMH: Evaluating the Risk of Major Malformations in Children Prenatally Exposed to Atypical Antipsychotics

Despite the increasing use of the newer “atypical” or second-generation antipsychotic agents to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders, we have relatively little data [...]

By |2021-03-29T10:51:11-04:00June 3rd, 2016|Antipsychotic Medications, Outcomes, Pregnancy & Medications, Research at CWMH, Risk of Malformations|Comments Off on New Research from the CWMH: Evaluating the Risk of Major Malformations in Children Prenatally Exposed to Atypical Antipsychotics

New Research from the CWMH: Newer Antipsychotics and Pregnancy

Despite the increasing use of the newer “atypical” or second-generation antipsychotic agents to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders, we have relatively little data [...]

By |2016-03-28T13:02:50-04:00March 10th, 2016|Antipsychotic Medications, Outcomes, Pregnancy & Medications, Research at CWMH, Risk of Malformations|Comments Off on New Research from the CWMH: Newer Antipsychotics and Pregnancy

New Research from the CWMH: Reassuring Data from the National Pregnancy Registry of Atypical Antipsychotics

Despite the increasing use of the newer “atypical” or second-generation antipsychotic agents to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders, we have relatively little data [...]

By |2016-03-28T13:02:50-04:00October 7th, 2015|Antipsychotic Medications, Outcomes, Pregnancy & Medications, Research at CWMH, Risk of Malformations|Comments Off on New Research from the CWMH: Reassuring Data from the National Pregnancy Registry of Atypical Antipsychotics

New Research from the CWMH: Omega-3 Fatty Acids for Atypical Antipsychotic-Associated Hypertriglyceridemia

Dyslipidemia is a common side effect of atypical antipsychotics and, for a significant number of patients, may limit the acceptabillily of this class of drugs as an option for long-term treatment. This open trial tested [...]

By |2016-03-29T15:29:06-04:00August 1st, 2015|Alternative & Complementary, Antipsychotic Medications, Research at CWMH|Comments Off on New Research from the CWMH: Omega-3 Fatty Acids for Atypical Antipsychotic-Associated Hypertriglyceridemia

In Brief: Study Finds No Link Between Antipsychotics and Gestational Diabetes

Given the number of younger women using atypical antipsychotic medications, we need more accurate data regarding the reproductive safety of these medications. To better understand the link between antipsychotic medication and medical conditions associated with [...]

By |2020-01-25T23:48:54-04:00May 18th, 2015|Antipsychotic Medications, Outcomes, Pregnancy & Medications, Pregnancy Outcomes|Comments Off on In Brief: Study Finds No Link Between Antipsychotics and Gestational Diabetes

Meta-Analysis: Antipsychotics and Pregnancy Outcomes

Second-generation or “atypical” antipsychotics, such as olanzapine (Zyprexa), aripiprazole (Abilify), and risperidone (Risperdal), are used far more frequently than are the first-generation or “typical” antipsychotics, such as haloperidol (Haldol). This is largely because the newer [...]

By |2015-07-08T11:30:14-04:00May 6th, 2015|Antipsychotic Medications, Outcomes, Pregnancy & Medications, Risk of Malformations|Comments Off on Meta-Analysis: Antipsychotics and Pregnancy Outcomes

Antipsychotics and Pregnancy Part 2: Preliminary Data from the MGH Pregnancy Registry

This is the second part of a two part series on the use of antipsychotic medications during pregnancy.  Read Part 1 here, which reviews data from the Australian antipsychotic registry.

By |2016-03-28T13:23:55-04:00August 6th, 2014|Antipsychotic Medications, Outcomes, Pregnancy & Medications, Risk of Malformations|Comments Off on Antipsychotics and Pregnancy Part 2: Preliminary Data from the MGH Pregnancy Registry

Antipsychotics and Pregnancy Part 1: Preliminary Data from the Australian Registry

This is the first part of a two part series on the use of antipsychotic medications during pregnancy. Atypical antipsychotic medications are commonly used for the treatment of schizophrenia and bipolar disorder. Despite the increasing [...]

By |2014-07-28T10:45:35-04:00July 28th, 2014|Antipsychotic Medications, Outcomes, Pregnancy & Medications, Risk of Malformations|Comments Off on Antipsychotics and Pregnancy Part 1: Preliminary Data from the Australian Registry

More Data on the Use of Atypical Antipsychotics During Pregnancy

Despite the use of the newer “atypical” antipsychotic agents to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders, three is relatively little data on the reproductive safety of these newer atypical agents.   

By |2024-04-14T16:17:26-04:00September 11th, 2013|Antipsychotic Medications, Outcomes, Pregnancy & Medications, Risk of Malformations|Comments Off on More Data on the Use of Atypical Antipsychotics During Pregnancy
Go to Top